Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

A user tried microneedling for hair loss with a Dr. Pen at 0.8 mm and experienced bleeding, questioning if the intensity was too much. Others suggested a less aggressive approach, and one mentioned finasteride as a helpful treatment without side effects.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

The post and conversation are about a user's progress with microneedling and minoxidil for hair loss. The user is happy with the progress and plans to continue with the treatment, without using finasteride.

The conversation discusses the uncertainty of the legitimacy of minoxidil products in the EU market and mentions baricitinib as an approved, but expensive alternative. A method to test for real minoxidil involves mixing it with bleach to see if it turns orange or brown.

A user plans to create a custom topical solution by adding finasteride, caffeine, cetirizine, and melatonin to a minoxidil bottle, questioning the stability and effectiveness of this mix. Concerns include potential crystallization and solution muddiness with added ingredients.

Scientists discovered a sugar gel, 2dDR-SA, that increased hair growth in mice. Users discussed its potential, comparing it to other treatments like Minoxidil and finasteride.

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.

The conversation discusses potential hair regrowth after one month of using minoxidil combined with microneedling. It's suggested that there might be progress, but one month is too soon to determine effectiveness.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

A person is experimenting with microneedling on one temple while using Minoxidil to address hair loss. They plan to needle weekly and apply Minoxidil twice daily, avoiding application around needling sessions.

Minoxidil and microneedling are causing new hair growth, particularly in the center of the hairline, creating a more prominent M shape. Users discuss the progress and potential benefits of the treatment.

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

A 31-year-old used topical minoxidil and finasteride with weekly microneedling for 3.5 weeks, seeing improvements in the crown and frontal areas. They are happy with the results and curious about the 3-month mark.

Autologous exosome treatment for hair loss is being discussed as an emerging option. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.

Users discussed adding microneedling to minoxidil treatment for hair loss. Some saw improvements, especially when combining microneedling with minoxidil and finasteride, while others did not notice significant changes.

A user shared their one-month progress using Minoxidil and RU58841 for hair loss, noting significant shedding after micro-needling and seeking opinions on their regrowth. They stopped micro-needling and added RU58841 to their treatment.

A user did not respond to finasteride, dutasteride, and oral minoxidil for hair loss after four years of treatment and is considering scalp micropigmentation (SMP). Other users suggest the hair loss pattern may indicate alopecia areata and recommend seeing a dermatologist.

The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.

The conversation is about concerns and advice regarding microneedling for hair loss, with potential risks like chronic inflammation, scarring, and folliculitis. The user has been using minoxidil, finasteride, and stemoxydine with good results and is considering adding microneedling, with recommendations for using a dermastamp or pen.

Using minoxidil and finasteride to address hair loss, with questions about side effects and the possibility of microneedling for increased effectiveness.

RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.

A user discusses their rapidly receding hairline and a prescribed topical solution containing 7% Minoxidil, 0.1% Finasteride, and 3% biotinoyl tripeptide. The solution is a custom compound from their dermatologist, costing $50 for a one-month supply.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user shared progress pictures showing improvement in hair growth after one year of using finasteride and minoxidil. They are considering microneedling to further improve their hairline and have chosen to use a derma stamp.